Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

Trial Profile

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs TPI 287 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Cortice Bioscience
  • Most Recent Events

    • 27 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 20 Nov 2015 Results published in a Cortice Biosciences media release.
    • 09 Nov 2015 Results from this trial will be presented at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day according to a Cortice Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top